LabGenius Therapeutics, a pioneering drug discovery firm integrating machine learning and high-throughput experimentation for enhancing therapeutic antibodies, disclosed a significant research collaboration with LG Chem. The multi-year agreement includes an option and licensing deal, with a focus on developing innovative multispecific antibodies to address drawbacks in current immunotherapies, such as on-target, off-tumor toxicities. This collaboration is strategic and aims to leverage cutting-edge technology to advance the field of drug discovery.